Odronextamab demonstrated a 48.3% objective response rate and 31.7% complete response rate in R/R DLBCL patients post-CAR-T therapy. The median duration of response was 14.8 months, with ...

Video content above is prompted by the following: Thanks to all of you for this rich and informative discussion. Before we conclude, I’d like to get final thoughts from each of you.

The FDA has turned down a pair of marketing applications for Regeneron’s CD20xCD3 bispecific antibody odronextamab to treat two common forms of non-Hodgkin lymphoma (NHL). The decision throws a ...

The company is advancing several promising R&D programs, including pivotal data expected for Linvoseltamab in multiple myeloma and odronextamab in follicular lymphoma. Regeneron Pharmaceuticals ...

driven by the expanded labels of Eylea HD and Libtayo and by the potential launches of Ordspono (odronextamab), linvoseltamab, itepekimab, pozelimab/cemdisiran, and the novel oncology combination ...

odronextamab, and itepekimab. At the same time, when forecasting the growth rates of revenue and net income of the New York-based company, I took into account, among other things, the decline in ...

CD3e molecule, epsilon (CD3E), is a single-pass type I membrane glycoprotein found on T cells. It contains one Ig-like (immunoglobulin-like) domain and one ITAM domain. CD3E, along with CD3-gamma ...

We expect regulatory approvals for linvoseltamab in relapsed/refractory multiple myeloma, odronextamab in late-line follicular lymphoma, and the aforementioned Libtayo indication in adjuvant CSCC.

The FDA has started a priority review of Regeneron’s CD20xCD3 bispecific antibody odronextamab, seeking a broader label than other drugs in the class. The US regulator is reviewing odronextamab ...